Thomas Cahill - 24 Oct 2022 Form 4 Insider Report for Prime Medicine, Inc. (PRME)

Role: Director
Signature: /s/ Carman Alenson attorney-in-fact
Issuer symbol: PRME
Transactions as of: 24 Oct 2022
Net transactions value: +$6,800,000
Form type: 4
Filing time: 26 Oct 2022, 20:00:34 UTC
Previous filing: 19 Oct 2022
Next filing: 16 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PRME	Common Stock	Conversion of derivative security		+4,905,679			4,905,679	24 Oct 2022	By Newpath Partners, L.P.	F1, F2
transaction	PRME	Common Stock	Purchase	$6,800,000	+400,000	+8.2%	$17.00	5,305,679	24 Oct 2022	By Newpath Partners, L.P.	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PRME	Series A Convertible Preferred Stock	Conversion of derivative security	$0	-9,999,999	-100%	$0.000000^*	0	24 Oct 2022	Common Stock	3,216,674		By Newpath Partners, L.P.	F1, F2
transaction	PRME	Series B Convertible Preferred Stock	Conversion of derivative security	$0	-5,250,781	-100%	$0.000000^*	0	24 Oct 2022	Common Stock	1,689,005		By Newpath Partners, L.P.	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the "Preferred Stock") were convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on October 24, 2022. The Preferred Stock had no expiration date.
F2	Represents shares held directly by Newpath Partners, L.P. ("Newpath LP"). Newpath Partners GP, L.P. ("Newpath GP LP") is the general partner of Newpath LP. Newpath Partners GP, LLC ("Newpath GP LLC") is the general partner of Newpath GP LP. The Reporting Person is a managing member of Newpath GP LLC, and disclaims beneficial ownership of the shares held directly by Newpath LP except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
F3	Reflects shares purchased by Newpath LP in the Issuer's initial public offering.